• Balance Sheet
  • Income Statement
  • Cashflow Statement

Currency Code (in millions)
2021 FY
USD
2022 FY
USD
2023 FY
USD
2024 FY
USD
2025 Q2 YTD
USD
Assets
Cash and cash equivalents 4,544 4,030 3,686 3,127 1,287
Receivables 47 48 71 177 241
Receivable from the sale of IQOS System commercialization rights 0 1,721 NA NA NA
Inventories
Leaf tobacco 744 704 649 591 475
Other raw materials 166 186 204 190 200
Work in process 23 24 22 21 21
Finished product 261 266 340 278 320
Total 1,194 1,180 1,215 1,080 1,016
Other current assets 298 138 117 36 88
Total current assets 6,083 7,220 5,585 4,513 2,632
Income taxes NA 103 496 93 NA
Property, plant and equipment, at cost 4,432 4,427 4,582 4,537 4,530
Less accumulated depreciation 2,879 2,819 2,930 2,920 2,920
Total 1,553 1,608 1,652 1,617 1,610
Property, plant and equipment, at cost
Land and land improvements 123 123 123 124 NA
Buildings and building equipment 1,422 1,478 1,535 1,552 NA
Machinery and equipment 2,652 2,578 2,684 2,662 NA
Construction in progress 235 248 240 199 NA
Goodwill 5,177 5,177 6,791 6,945 6,072
Other intangible assets, net 12,306 12,384 13,686 12,973 12,900
Investments in equity securities 13,481 9,600 10,011 8,195 8,143
Other assets 923 965 845 934 975
Total Assets 39,523 36,954 38,570 35,177 32,332
Liabilities
Current portion of long-term debt 1,105 1,556 1,121 1,527 1,069
Accounts payable 449 552 582 700 569
Accrued liabilities
Marketing 664 599 716 688 894
Settlement charges 3,349 2,925 2,563 2,354 1,098
Other 1,365 1,299 1,902 1,780 1,435
Dividends payable 1,647 1,685 1,735 1,732 1,723
Total current liabilities 8,579 8,616 11,319 8,781 6,788
Long-term debt 26,939 25,124 25,112 23,399 23,651
Deferred income taxes 3,692 2,897 2,799 3,749 3,661
Accrued pension costs 200 133 130 136 133
Accrued postretirement health care costs 1,436 1,083 1,079 935 935
Other liabilities 283 324 1,621 365 370
Total liabilities 41,129 40,877 42,060 37,365 35,538
Deferred gain from the sale of IQOS System commercialization rights 0 0 2,700 0 NA
Stockholders' Equity (Deficit)
Common stock 935 935 935 935 935
Additional paid-in capital 5,857 5,887 5,906 5,905 5,895
Earnings reinvested in the business 30,664 29,792 31,094 35,516 35,525
Accumulated other comprehensive losses (3,056) (2,771) (2,673) (2,400) (2,831)
Cost of repurchased stock (36,006) (37,816) (38,802) (42,194) (42,780)
Total stockholders' equity (deficit) attributable to Altria (1,606) (3,973) (3,540) (2,238) (3,256)
Noncontrolling interest 0 50 50 50 50
Total stockholders' equity (deficit) (1,606) (3,923) (3,490) (2,188) (3,206)
Total Liabilities and Stockholders' Equity (Deficit) 39,523 36,954 38,570 35,177 32,332

Currency Code (in millions)
2021 FY
USD
2022 FY
USD
2023 FY
USD
2024 FY
USD
2025 Q2 YTD
USD
Net revenues 26,013 25,096 24,483 24,018 11,361
Cost of sales 7,119 6,442 6,218 6,077 2,710
Excise taxes on products 4,902 4,408 3,981 3,574 1,552
Gross profit 13,992 14,246 14,284 14,367 7,099
Marketing, administration and research costs 2,432 2,327 2,737 2,737 1,207
Asset impairment and exit costs NA NA NA 389 1
Impairment of goodwill NA NA NA NA 873
Operating income 11,560 11,919 11,547 11,241 5,018
Interest and other debt expense, net 1,162 1,058 989 1,037 537
Net periodic benefit income, excluding service cost (202) (184) (127) (102) (29)
(Income) losses from investments in equity securities 5,979 3,656 (243) (652) (291)
Gain on the sale of IQOS System commercialization rights NA NA NA (2700) NA
Earnings before income taxes 3,824 7,389 10,928 13,658 4,801
Provision for income taxes 1,349 1,625 2,798 2,394 1,346
Net earnings 2,475 5,764 8,130 11,264 3,455
Per share data
Basic and diluted earnings per share 1.34 3.19 4.57 6.54 2.04
Condensed Consolidated Statements of Comprehensive Earnings
Net earnings 2,475 5,764 8,130 11,264 3,455
Other comprehensive earnings (losses), net of deferred income taxes
Benefit plans 808 176 (57) 101 3
ABI 426 143 174 177 (414)
Currency translation adjustments and other 51 (34) (19) (5) (20)
Other comprehensive earnings (losses), net of deferred income taxes 1,285 285 98 273 (431)
Comprehensive earnings 3,760 6,049 8,228 11,537 3,024

Currency Code (in millions)
2021 FY
USD
2022 FY
USD
2023 FY
USD
2024 FY
U
SD
2025 Q2 YTD
USD
Cash Provided by (Used in) Operating Activities
Net earnings 2,475 5,764 8,130 11,264 3,455
Adjustments to reconcile net earnings to operating cash flows
Depreciation and amortization 244 226 272 286 142
Deferred income tax provision (benefit) (1,160) (947) (230) 951 33
Unrecognized tax benefit (21) 16 1,111 (1,128) 0
Fair value adjustment for NJOY Transaction contingent payments NA NA NA NA 25
(Income) losses from investments in equity securities 5,979 3,656 (243) (652) (291)
Gain on the sale of IQOS System commercialization rights NA 0 0 (2,700) NA
Asset impairment and exit costs, net of cash paid NA NA NA (354) 4
Impairment of goodwill NA NA NA NA 873
Dividends from ABI 119 104 163 139 181
Cash effects of changes
Receivables (18) (21) 6 (106) (62)
Inventories 57 14 (15) 102 27
Accounts payable 163 92 38 116 (123)
Income taxes (149) (118) 6 798 267
Accrued liabilities and other current assets 165 (129) 280 (550) (489)
Accrued settlement charges (215) (424) (362) (209) (1,256)
Loss on Cronos-related financial instruments 148 NA NA NA NA
Loss on early extinguishment of debt 649 NA NA NA NA
Asset impairment and exit costs NA 0 0 389 NA
Pension plan contributions (26) (20) (20) (18) (9)
Pension and postretirement, net (175) (156) (136) (107) (37)
Other, net 170 199 287 178 193
Net cash provided by (used in) operating activities 8,405 8,256 9,287 8,753 2,925
Cash Provided by (Used in) Investing Activities
Capital expenditures (169) (205) (196) (142) (70)
Proceeds from the ABI Transaction NA 0 0 2,353 0
Other, net 205 (13) (36) (36) (9)
Cash Provided by (Used in) Financing Activities
Proceeds from the sale of IQOS System commercialization rights 0 1,000 1,700 0 NA
Proceeds from the Ste. Michelle Transaction, net of cash transferred 1,176 NA NA NA NA
Acquisition of NJOY, net of cash acquired 0 0 (2,751) 0 NA
Net cash provided by (used in) investing activities 1,212 782 (1,283) 2,175 (79)
Long-term debt issued 5,472 0 998 0 997
Long-term debt repaid (6,542) (1,105) (1,566) (1,121) (1,607)
Repurchases of common stock (1,675) (1,825) (1,000) (3,400) (600)
Dividends paid on common stock (6,446) (6,599) (6,779) (6,845) (3,454)
Other, net (215) (12) (27) (125) (29)
Net cash provided by (used in) financing activities (10,029) (9,541) (8,374) (11,491) (4,693)
Proceeds from short-term borrowings 0 0 2,000 0 NA
Repayment of short-term borrowings 0 0 (2,000) 0 NA
Premiums and fees related to early extinguishment of debt (623) NA NA NA NA
Cash, cash equivalents and restricted cash
Increase (decrease) (412) (503) (370) (563) (1,847)
Balance at beginning of period 5,006 4,594 4,091 3,721 3,158
Balance at end of period 4,594 4,091 3,721 3,158 1,311